Rituxan

Report: Don't count Celltrion out of Rituxan biosim race

Report: Don't count Celltrion out of Rituxan biosim race

Fierce Biotech

Novartis’s Biosimilar Rituxan Is ‘On Track,’ Sandoz Head Says

Novartis’s Biosimilar Rituxan Is ‘On Track,’ Sandoz Head Says

Bloomberg

Roche’s GA101 Met Goals in Stage One of Trial to Replace Rituxan

Roche’s GA101 Met Goals in Stage One of Trial to Replace Rituxan

Bloomberg

Boehringer Testing Copy of Rituxan in Type of Lymphoma

Boehringer Testing Copy of Rituxan in Type of Lymphoma

Bloomberg

Good News For Biogen's $7 Billion Rituxin: Copying Drugs Bio Drugs Ain't Easy

Good News For Biogen's $7 Billion Rituxin: Copying Drugs Bio Drugs Ain't Easy

Forbes

Roche Faces New Foe as Boehringer Plans a Rituxan Copy

Roche Faces New Foe as Boehringer Plans a Rituxan Copy

Bloomberg

Roche expects to keep Rituxan monopoly until 2015

Roche expects to keep Rituxan monopoly until 2015

Fierce Pharma

Rituxan And Its Biosimilar Competitors

Rituxan And Its Biosimilar Competitors

Seeking Alpha

Sanofi Loses Appeal in Roche Suit Over Rituxan, Avastin

Sanofi Loses Appeal in Roche Suit Over Rituxan, Avastin

Bloomberg

Fake Avastin may not be the only counterfeit on doctors' shelves

Fake Avastin may not be the only counterfeit on doctors' shelves

Fierce Pharma